NeuroCytonix has filed a notice of an exempt offering of securities to raise $4,010,337.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, NeuroCytonix is raising $4,010,337.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Laurent Lavigneducadet played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About NeuroCytonix
NeuroCytonix Inc, is an emerging biotechnology company founded in January 2017 to develop and exploit disruptive medical technologies for regeneration of the nervous system. NeuroCytonix has developed a cutting-edge medical biotechnology business focused on tissue engineering and regeneration. This technology and its related protocols are dramatically improving the treatment of neurodegenerative diseases such as Alzheimers, Stroke, Parkinsons, Autism, Cerebral Palsy and Schizophrenia.
To learn more about NeuroCytonix, visit http://www.neurocytonix.com/
Contact:
Laurent Lavigneducadet, Chief Financial Officer
240-243-6455
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.